About Glycostem Therapeutics

Glycostem Therapeutics is a Netherlands based lifescience company advancing the science of cellular immunotherapy by creating breakthroughs in the expansion and differentiation of hematopoietic stem cells.

Glycostem Therapeutics has developed a new and innovative cell culture system for the ex-vivo generation of clinically relevant amounts of NK-cells.   

Glycostem Therapeutics pursues an open project collaboration policy towards joint development of cellular immunotherapeutics for treatment of leukemia, lymphomas and other forms of cancer.   

Research

Glycostem Therapeutics has achieved groundbreaking results on the ex vivo generation of functional human
NK cells from Umbilical Cord Blood CD34+ stem and progenitor cells under
controlled GMP-compliant conditions.

Miller et al. Blood 2005; Rubnitz et al. JCO 2010; Curti et al. Blood 2011 have
successfully shown that NK cells can be isolated from the blood of haploidentical
donors and used for cellular immunotherapy in AML patients.

Still there is no breakthrough for NK cellular therapy, due to low NK cell
numbers, low activation status and residual T- and B-cells in current
clinically used NK cellular products.

Glycostem Therapeutics' ex-vivo generation method goes beyond the state of the
art, enabling the production of large scale batches of clinically relevant
amounts of active anti-tumor NK cells from cord blood.

Interestingly ex vivo generated NK
cells are devoid of B- and T-cells , meaning that adverse effects such as GVHD
and/or Lymphoma can be excluded.

Ex vivo generated NK cells are currently explored for anti-leukemic
immunotherapy in a phase I trial with elderly AML-patients.

Glycostem Therapeutics' product development portfolio will be extended to other obvious NK cellular therapy targets in hematology and oncology, such as
Multiple Myeloma, Melanoma, hepatocellular carcinoma or breast cancer.